The NASS Podcast

Featuring: Evan K. Johnson, PT, DPT, OCS and Rick J. Placide, MD, PT

Disclosures:

Johnson, Evan K. : Nothing to Disclose.  

Placide, Rick J. : Nothing to Disclose.

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Sandeep N. Gidvani, MD and Nickul Jain, MD

Disclosures:

Gidvani, Sandeep N.: Consulting: Xenco Medical (B), SeaSpine (None), Spinal Balance (None), SI-BONE (None), NuVasive (None).  

Jain, Nickul: Consulting: Spineart (Future Compensation Expected); Research Support (Staff and/or materials): Globus Medical (Nonfinancial).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Sandeep N. Gidvani, MD and Paul R. Gause, MD

Disclosures:

Gause, Paul R. : Speaking and/or Teaching Arrangements: Medtronic (C). 

Gidvani, Sandeep N. : Consulting: Xenco Medical (B), SeaSpine (None), Spinal Balance (None), SI-BONE (None), NuVasive (None).  

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: E. Kano Mayer, MD; Eeric Truumees, MD; Mark Cuccuzella, MD

Disclosures:

Cuccuzella, Mark: Nothing to Disclose.

Mayer, E. Kano: Stock Ownership: Infinite Orthopedics (1%); Private Investments: Lanai Health Solutions (30%); Speaking and/or Teaching Arrangements: North America Spine Society (B); Trips/Travel: NASS (B).  

Truumees, Eeric: Trips/Travel: AAOS (Travel Expense Reimbursement); Board of Directors: Seton Family of Doctors (Salary); Other Office: AAOS Communications Cabinet (E, Travel Expense Reimbursement, Editor-in-Chief of AAOS Now); Research Support - Staff and/or Materials: Relievant (B, Paid directly to institution/employer), Medtronic (A), Vertex Pharma (A), Dova Pharmaceuticals (A), Pfizer (B, Paid directly to institution/employer), Stryker Spine (B, Paid directly to institution/employer).  

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Zorica Buser, PhD and Mark Erwin, DC, PhD

Disclosures:

Buser, Zorica: Consulting: AOSpine (B, Outside 12-Month Requirement), Xenco Medical (B, Outside 12-Month Requirement); Research Support (Investigator Salary): SeaSpine (F, Paid directly to institution/employer); Research Support (Staff and/or materials): Next Science (F, Paid directly to institution/employer), SeaSpine (F, Paid directly to institution/employer); Trips/Travel: AO Spine (Travel reimbursements for AO Spine Knowledge forum meetings and congresses).  

Erwin, Mark: Board of Directors: Notogen (Stock Ownership disclosed); Grants: Skoll Family Trust (G,Paid directly to institution/employer); Research Support (Investigator Salary): Canadian Chiropractic Research Foundation (D); Research Support (Staff and/or materials): Skoll Family Trust (F, Paid directly to institution/employer); Scientific Advisory Board: Notogen (Stock Ownership dislcosed); Stock Ownership (including options, warrants): Notogen Inc (33%).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Matthew L. Goodwin, MD, PHD (Washington University), Dan Sciubba, MD (Johns Hopkins), and Joe Schwab, MD, MS (Harvard/Massachusetts General Hospital)

Use of bone cement in the spine has been marred by early controversy, including debate over kyphoplasty/vertebroplasty and whether use of bone cement in spine surgery was safe or effective.  Now with recent publications reviewing almost 20 years of cement use in the spine, the data are relatively convincing that bone cement in spine surgery is not only useful, but also relatively safe.  

In this podcast, these spine tumor surgeons from NASS' Section on Spine Oncology discuss the history of bone cement in the spine, the current use/indications for cement (e.g. metastatic spinal disease, osteoporosis), current techniques (e.g. through fenestrated pedicle screws), and discuss potential complications as well as practical tips for employing these techniques.

Disclosures:

Goodwin, Matthew L.: Consulting: Augmedics (A); Fellowship Support: AO Spine  (Salary, Fellowship Support), NREF (Salary, Fellowship Support); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement).

Sciubba, Daniel M.: Consulting: Baxter (B), DePuy-Synthes (B), Globus (B), Medtronic (C), Nuvasive (B), Stryker (C).

Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Did you know that physicians, as a group, have lower work-life satisfaction compared to the general population? The consequences of burnout are borne both by the individual physician and the health care system. The recognition of burnout as a serious individual and institutional challenge is leading to an increased need to design, implement, and evaluate systems that promote well-being.

Moderator Richard L. Skolasky, Jr., Sc.D. interviews Todd Albert, MD and Eric Muehlbauer, MJ, CAE on this very important topic to assist the listener in ultimately being able to identify and strategize to mitigate risk factors in their own lives or in the organization that they represent.

Disclosures:

Albert, Todd J.: Board of Directors: American Orthopaedic Association (Nonfinancial, Treasurer-Elect), Hospital For Special Surgery (None, Surgeon-in-Chief Emeritus and Medical Director), Scoliosis Research Society (Nonfinancial, Past President); Consulting: Nuvasive (B); Other: JP Medical Publishers (B), Saunders/Mosby- Elsevier (B), Springer (A), Thieme Medical Publishers (B); Research Support (Staff and/or materials): PCORI (D); Royalties: DePuy Synthes Spine (F); Stock Ownership: ASIP (D), Augmedics (F), Biomerix (D, 42,253 Shares), Bonovo Orthopedics (D, 85,737 Shares), Crosstrees Medical  (D,  <1%), Cytodyn Inc. (F), Gentis (D), Innovative Surgical Designs (F), InVivo Therapeutics (C, <1%. Advisory Board, Stock options.), Invuity  (C, <1%. Member of Advisory Board, stock options.), Morphogenesis (E), Paradigm Spine, LLC (F, <1%.), Physician Recommended Nutriceuticals (D), PMIG (D), Pulse Equity (F), Spinicity  (D, <1%.), Strathspey Crown (F), Surg.IO (E), Vital 5 (None, <1%. Advisory Board, Stock Holder), Zimmer Biomet  (F).

Muehlbauer, Eric J.: Nothing to Disclose  

Skolasky, Richard L.: Board of Directors: North American Spine Society (Nonfinancial, Governance Committee, Chair Research Program Management, Chair Board of Directors, voting member); Other: International Society For Quality Of Life Research (Nonfinancial, Associate Editor for Quality of Life Research).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: F. Todd Wetzel, MD; Carrie A. Diulus, MD; Mark Cuccuzella, MD

Disclosures:

Cuccuzella, Mark : Nothing to Disclose

Diulus, Carrie A. : Trips/Travel: NASS (Travel Expense Reimbursement).  

Wetzel, F. Todd : Stock Ownership: Relievant Medical (1%). 

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Lawrence G. Lenke, MD; Evan K. Johnson, PT, DPT, OCS; Neel Anand, MD

Disclosures:

Anand, Neel: Royalties: Medtronic (F), Nuvasive (B), Globus Medical (B), Elsevier (B); Stock Ownership: Globus (, unknown), Medtronics (, unknown); Private Investments: Paradigm Spine (, 1%, unknown), Bonovo Orthopaedics (, 1%, unknown), Pearl Diver (, 1%, unknown), Theracell (, 1%, unknown), GYS Tech (, 1%, unknown); Consulting: Spinal solutions (Financial, Stock options : Unknown ); Speaking and/or Teaching Arrangements: Medtronic (Financial, 42000); Trips/Travel: Medtronic (Financial, Included with consulting fees); Scientific Advisory Board: Globus Medical (Financial, 0).

Johnson, Evan K. : Nothing to Disclose.

Lenke, Lawrence G.: Consulting: DePuy Synthes (D, Outside 12-Month Requirement), K2M (D, Outside 12-Month Requirement), Medtronic (I, Outside 12-Month Requirement, Paid directly to institution/employer); Device or Biologic Distribution Group (Physician-Owned Distributorship): Medtronic (I), Quality Medical Publishing  (A); Grants: Fox Family Foundation (A); Other: AOSpine (D, Paid directly to institution/employer), Broadwater (B), Scoliosis Research Society (B), The Spinal Research Foundation (Travel Expense Reimbursement); Research Support (Staff and/or materials): EOS Imaging (A), Setting Scoliosis Straight Foundation (A).  

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Moderator Douglas Pahl, MD interviews Karthik Madhavan, MD about a SpineLine articled he helped author titled, "Augmented Reality, Virtual Reality and Artificial Intelligence: Are We There Yet?". Dr. Madhavan talks about the exciting developments with augmented reality and how there is still much to learn in the cutting-edge technology.

This article first appeared in the January/February 2020 edition of SpineLine.

Access the article here. 

Disclosures:

Madhavan, Karthik : Nothing to Disclose  

Pahl, Douglas W.: Consulting: Stryker (C, Outside 12-Month Requirement, Paid directly to institution/employer); Other: Orthofix (A, Outside 12-Month Requirement); Stock Ownership: Nanovis (14,837 Shares, Paid directly to institution/employer), Trainer Rx (<1%), Vertera (D, Paid directly to institution/employer); Trips/Travel: Astrazeneca (A, Outside 12-Month Requirement), Boston Scientific (B, Outside 12-Month Requirement), DePuy/Synthes (A, Outside 12-Month Requirement), DJO (A, Outside 12-Month Requirement), Globus (A, Outside 12-Month Requirement), Horizon (A, Outside 12-Month Requirement), Medtronic (A, Outside 12-Month Requirement), Stryker (B, Outside 12-Month Requirement), Zimmer/Biomet (C, Outside 12-Month Requirement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5